Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy

Journal of Veterinary Internal Medicine

Volumn 22, Issue 4, 2008, Pages 897-904

  O'Grady, Michael R ^a   Minors, S L ^b   O'Sullivan, M L ^a   Horne, R ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b Mississauga Oakville Veterinary Emergency Hospital and Referral Group   (Canada)

Author keywords

Congestive heart failure; Dilated cardiomyopathy; Doberman Pinscher; Mortality; Pimobendan

Indexed keywords

BENAZEPRIL; BENZAZEPINE DERIVATIVE; CARDIOTONIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; PIMOBENDAN; PYRIDAZINE DERIVATIVE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DRUG ADMINISTRATION; ELECTROCARDIOGRAPHY; HEART FAILURE; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZAZEPINES; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; DIURETICS; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FUROSEMIDE; HEART FAILURE; PYRIDAZINES;

ANIMALIA; CANIS FAMILIARIS;

EID: 47849128375     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2008.0116.x     Document Type: Article

References (33)

1. Sisson DD, Thomas WP. Myocardial diseases. In: Ettinger SJ, ed. Textbook of Veterinary Internal Mediane. Diseases of the Dog and Cat, 4th ed. Philadelphia, PA: WB Saunders; 1995:995-1032.
2. Buchanan JW. Causes and prevalence of cardiovascular disease. In: Kirk RW, Bonagura JD, eds. Current Veterinary Therapy XI. Philadelphia, PA: WB Saunders: 1992:647-654.
3. Calvert CA, Meurs KM. CVT Update: Doberman pinscher occult cardiomyopathy. In: Bonagura JD, ed. Current Veterinary Therapy XIII. Philadelphia, PA: WB Saunders; 2000:756-760.
4. O'Grady MR. DCM in Doberman Pinschers: Lessons learned in the first decade of study. Proceedings 20th ACVIM Forum 2002;114-115.
5. O'Grady MR, O'Sullivan ML. Dilated cardiomyopathy: An update. Vet Clin Small Anim 2004;34:1187-1207.
6. Calvert CA, Jacobs GJ, Pickus CW, et al. Signalment, survival, and prognostic factors in Doberman Pinschers with end-stage cardiomyopathy. J Vet Int Med 1997;11:323.
7. The COVE Study Group. Controlled clinical evaluation of enalapril in dogs with heart failure: Results of the Cooperative Veterinary Enalapril Study Group. J Vet Int Med 1995;9:243-252.
8. The IMPROVE Study Group. Acute and short-term hemodynamics, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: Results of the Invasive Multicenter Prospective Veterinary Evaluation of Enalapril Study. J Vet Int Med 1995;9:234-242.
9. Ettinger SJ, Benitz AM, Ericsson GF, et al. Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group. J Am Vet Med Assoc 1998;213:1573-1577.
10. The BENCH (Benazepril Hydrochloride in Canine Heart Disease) Study Group. The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure: Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial. J Vet Cardio 1999;1:7-18.
11. Van Meel JCA, Dierden W. Hemodynamic profile of the cardiotonic agent pimobendan. J Cardiovasc Pharm 1989;14(Suppl 2):S1-S6.
12. 2+ activation and the inotropic effect of pimobendan: Comparison with milrinone. Circ Res 1988;63:911-922.
13. Pouleur H, Hanet C, Schroder E, et al. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure. J Cardiovasc Pharmacol 1989;14(Suppl 2):S18-S22.
14. 2+ sensitization. Mol Cell Biochem 1996;157:245-249.
15. Sato N, Asai K, Okumura S, et al. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Am J Physiol 1999;276:H1699-H1705.
16. Hagemeijer F. Calcium sensitization with pimobendan; pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure. Eur Heart J 1993;14: 551-566.
17. Verdouw PD, Hartog JM, Duncker DJ, et al. Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 1986;126:21-30.
18. Sasaki T, Kubo T, Komamura K, Nishikimi T. Effect of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure. J Cardio 1999;33:317-325.
19. Erlemeier HH, Kupper W, Bleifield W. Comparison of hormonal and hemodynamic changes after long-term therapy with pimobendan or enalapril - A double-blind randomised study. Eur Heart J 1991;12:889-899.
20. Baumann G, Ningel K, Permanetter B. Cardiovascular profile of UD-CG 115BS - Pimobendan and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idopathic dilated cardiomyopathy. J Cardiovasc Pharmacol 1989;13:730-738.
21. Asanoi H, Ishizaka S, Kameyama T, et al. Disparate inotropic and lusitropic response to pimobendan in conscious dogs with tachycardia-induced heart failure. J Cardiovasc Pharmacol 1994;23:268-274.
22. Iwasaki A, Matsumori A, Yamada T, et al. Pimobendan inhibits the production of proinflammatory cytokines and gene expression of inducible nitric oxide synthase in a murine model of viral myocarditis. J Am Coll Cardio 1999;33:1400-1407.
23. Fuentes VL, Corcoran B, French A, Schober KE, et al. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Int Med 2002;16:255-261.
24. Lombard CW. Pimobendan in congestive heart failure. Proceedings 21st ACVIM Forum 2003;104.
25. Lombard CW. Pimobendan in mitral regurgitation versus dilated cardiomyopathy. Proceedings 22nd ACVIM Forum 2004; 97-98.
26. The EPOCH Study Group. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild-to-moderate heart failure - The effects of pimobendan on chronic heart failure study. Circ J 2002;66:149-157.
27. Smith PJ, French AT, Van Israel N, et al. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract 2005;46:121-130.
28. Lombard CW, Jones O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc 2006;42:249-261.
29. Buchanan JW, Bucheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995;206:194-199.
30. Givertz MM, Colucci WS, Braunwald E. Clinical aspects of heart failure; pulmonary edema, high-output failure. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed. Philadelphia, PA: Elsevier Saunders; 2005:551-555.
31. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE study research group. N Engl J Med 1991;325:1468-1475.
32. Lubsen J, Just H, Hjalmarsson AC, et al. Efficacy of pimobendan on exercise capacity in patients with heart failure: Main results from the pimobendan in congestive heart failure (PICO) trial. Heart 1996;76:223-231.
33. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival Analysis Part IH: Multivariate data analysis - Choosing a model and assessing its adequacy and fit. Br J Cancer 2003;89:606-611.